Abbott touts global launch of 1st-of-its-kind bioresorbable drug-eluting stent

Wed, 09/26/2012 - 4:31pm
Mass Device

Abbott launches the "world's 1st drug-eluting bioresorbable vascular scaffold" in more than 30 countries across Europe, parts of Asia Pacific and Latin America.

Abbott logo

Right on schedule, Abbott (NYSE:ABT) touted the launch of its Absorb device, which it calls the world's first drug eluting bioresorbable vascular scaffold.

Absorb, which won CE Mark approval in the European Union in January 2011, is now available across Europe and in parts of Asia Pacific and Latin America, the company announced yesterday. The healthcare giant had stated previously that it would launch commercially by the end of 2012.

Abbott consultant and Netherlands cardiologist Dr. Patrick Serruys waxed poetic about the potential for a fully resorbable stent system.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.